NCT00753038 - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

May 31, 2013

Conditions

Carcinoma, Squamous Cell of the Head and Neck

Interventions

BIOLOGICAL

REOLYSIN®

3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle

DRUG

Carboplatin

5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

DRUG

Paclitaxel

175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle

Trial Locations (2)

Montefiore Medical Center, The Bronx

Cancer Therapy and Research Center at UTHSCSA, San Antonio